Page last updated: 2024-10-24

integrin alpha7-beta1 complex

Definition

Target type: cellularcomponent

An integrin complex that comprises one alpha7 subunit and one beta1 subunit. [PMID:12297042]

The integrin alpha7-beta1 complex is a transmembrane receptor that plays a crucial role in cell-matrix interactions. It is composed of two subunits: the alpha7 subunit and the beta1 subunit. The alpha7 subunit contains a large extracellular domain that interacts with the extracellular matrix (ECM) protein laminin. The beta1 subunit contains a transmembrane domain that anchors the complex to the cell membrane and a cytoplasmic domain that interacts with intracellular signaling molecules.

The cellular component of the integrin alpha7-beta1 complex is primarily the plasma membrane. This complex is located on the cell surface, where it binds to laminin in the ECM. Through this interaction, the integrin complex transmits signals from the ECM to the cell interior, influencing cell adhesion, migration, differentiation, and survival.

The integrin alpha7-beta1 complex also interacts with other cellular components, including the cytoskeleton. The cytoplasmic domain of the beta1 subunit binds to adaptor proteins, such as talin and kindlin, which link the integrin complex to the actin cytoskeleton. This connection allows the integrin complex to generate force and facilitate cell movement.

In addition to its role in cell adhesion and migration, the integrin alpha7-beta1 complex is also involved in various signaling pathways. Upon binding to laminin, the complex activates intracellular signaling cascades, leading to the activation of downstream effectors, such as kinases and transcription factors. These signaling pathways contribute to the regulation of gene expression, cell growth, and other cellular processes.

Overall, the integrin alpha7-beta1 complex is a crucial component of the cell membrane that plays a vital role in cell-matrix interactions. Its interactions with the ECM, cytoskeleton, and intracellular signaling pathways contribute to a wide range of cellular functions, including adhesion, migration, differentiation, and survival.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Integrin beta-1An integrin beta-1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P05556]Homo sapiens (human)

Compounds (17)

CompoundDefinitionClassesRoles
haloperidolhaloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.

Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol
antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
1,3-ditolylguanidine1,3-ditolylguanidine: structure given in first source; a selective ligand for the sigma binding sites in the braintoluenes
tirofibantirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group.

Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME.
L-tyrosine derivative;
piperidines;
sulfonamide
anticoagulant;
fibrin modulating drug;
platelet glycoprotein-IIb/IIIa receptor antagonist
arginyl-glycyl-aspartic acidarginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition systemoligopeptide
arginyl-glycyl-aspartyl-serinearginyl-glycyl-aspartyl-serine: corresponds to cell attachment site of fibronectin; located near carboxyl-terminal region of alpha-chain of fibrinogen; inhibits platelet aggregation & fibrinogen binding to activated platelets
glycyl-arginyl-glycyl-aspartyl-serineglycyl-arginyl-glycyl-aspartyl-serine: synthetic peptide from fibronectins; inhibits experimental metastasis of murine melanoma cells
d-arg-gly-asp-trparginyl-glycyl-aspartyl-tryptophan: a synthetic RGD-containing peptide
l 738167L 738167: structure in first source
cilengitideCilengitide: an alphaVbeta3 integrin antagonist that paralyzes cancer cellsoligopeptide
l 734217L 734217: fibrinogen receptor antagonist; structure given in first source
cyclopaminepiperidinesglioma-associated oncogene inhibitor
arginyl-glycyl-aspartyl-phenylalanine
cyclic(arg-gly-asp-d-phe-val)
mk-0429
mocetinostatmocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).

mocetinostat: undergoing phase II clinical trials for treatment of cancer
aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
tr 14035N-(2,6-dichlorobenzoyl)-4-(2',6'-bismethoxyphenyl)phenylalanine: TR-14035 is the (L)-isomer; an antagonist of both alpha4beta1 and beta7 integrins; structure in first source
bio 1211BIO 1211: integrin alpha4beta1 inhibitor; structure in first source